HER2 positive breast cancer
Conditions
Interventions
Observation group (single-arm study):Adjust the dose and duration of chemotherapy drugs
Sponsors
Chongqing General Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Female breast cancer patients aged >=18 years, who are planned to receive neoadjuvant treatment with trastuzumab emtansine injection (subcutaneous) in combination with docetaxel and carboplatin; 2.Patients with breast cancer confirmed as HER-2 positive (HER-2 immunohistochemistry staining 3+, or HER-2 immunohistochemistry staining 2+ and confirmed positive by FISH) organized by the central laboratory; 3.Conscious, without mental disorders, and with good compliance, can follow medical advice for treatment and follow-up; 4.Voluntarily join this study and have the ability to sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.HER-2 negative breast cancer patients; 2.Pregnant or planning to become pregnant and breastfeeding women; 3.Patients with allergic constitution and known or suspected allergy to drugs used in the study; 4.Patients who have participated or plan to participate in other clinical trials within the past 4 weeks; 5.Other circumstances where the researcher believes it is not appropriate to participate in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response rate, pCR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor shrinkage rate;Security Analysis;Overall Response Rate; | — |
Countries
China
Contacts
Public ContactChai Fan
Chongqing General Hospital
Outcome results
None listed